A report from the National Cancer Institute on the prevention and treatment of relapse after allogeneic transplantation discussing and making recommendations on the use of newer agents, the optimization of donor lymphocyte infusion (DLI), and the investigation of novel cellular therapies. Also discussed are novel ways to prevent relapse, including pre-emptive use of hypomethylating agents, cytoreduction before DLI, and combinations of targeted agents with DLI.
De Lima M, et al. Biol Blood Marrow Transplant
NCI Report: Prevention and Treatment of Relapse after Allo-HCT
Jan 2014